Coherus BioSciences, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coherus BioSciences, Inc. (CHRS) on May 26, 2021, covering events occurring on May 21 and May 22, 2021. The report details the results of the Company's 2021 Annual Meeting of Stockholders and the resignation of a Board member.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance data.
Material Changes and Corporate Events
- Board Resignation: V. Bryan Lawlis, Ph.D., resigned from the Board of Directors effective May 22, 2021. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Annual Meeting Results: The 2021 Annual Meeting was held virtually on May 21, 2021. Of 73,108,089 shares outstanding, 60,778,256 shares were voted.
- Director Elections (Proposal 1):
- Kimberly J. Tzoumakas: Elected with 53,926,419 votes FOR.
- Alan C. Mendelson: Elected with 49,727,753 votes FOR.
- V. Bryan Lawlis, Ph.D.: Received 24,858,425 votes FOR and 30,190,459 votes WITHHELD. He resigned prior to the conclusion of his term.
- Auditor Ratification (Proposal 2): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, with 60,619,946 votes FOR.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard disclosure regarding the director resignation.
Key Facts for Investor Verification
- Verify the strategic rationale for V. Bryan Lawlis's resignation and the composition of the Board following his departure.
- Confirm the voting breakdown for the director nominees, noting the significant number of withheld votes for Dr. Lawlis.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 9, 2021, for detailed background on the director nominees and auditor ratification.